Peer-reviewed journals

Worthley D, Cole S, Young G. (Letter to New England Journal of Medicine responding to Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross MD. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average risk population.) NEJM 2005; 352: 1384-1385.

Bampton PA, Sandford JJ, Cole SR, Smith A, Morcom J, Cadd B, Young GP. Interval faecal occult blood testing in a colonoscopy based screening program detects additional pathology. Gut 2005; 54: 803-806.

Levin B, Brooks D, Smith RA, Stone A.Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers.CA Cancer J Clin 2003; 53 (1): 44-55.

Smith R, Cokkinides V, Eyre H. American Cancer Society Guidelines for the Early Detection of Cancer. CA Cancer J Clin 2003; 53(1): 27-43.

Young GP, St John DJB, Cole SR, Bielecki BE, Pizzey C, Sinatra MA, Cadd B, Morcom J. Prescreening evaluation of a brush based faecal immunochemical test for haemoglobin. J Med Screen 2003; 3: 123-128.

Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003; 10: 117-122.

Cole SR, Young GP, Byrne D, Guy JR, Morcom J. Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner. J Med Screen 2002;9 (4):147-52.

Cole SR. Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Australia 2001; 175(4): 195-8.

Texts

Young GP, Rozen P, Levin B. How should we screen for early colorectal neoplasia? in Colorectal Cancer in Clinical Practice (Rozen P, Young GP, Levin B, Spann S). London: Martin Dunitz, 2002; 77-99.

Published Abstracts and Conference Presentations

Smith A, Cole SR, Young GP, Morcom J, LaPointe L, Chandler H. 2004. A quantifiable faecal immunochemical test (FIT) for haemoglobin facilitates balancing sensitivity with specificity when screening for colorectal cancer. J Gastroenterology and Hepatology 19 (Supp) A195.

Worthley DL, Cole SR, Mehaffey S, Smith A, Turnbull D, Young GP. 2004. A questionnaire based assessment of barriers to participation in faecal occult blood test screening for colorectal cancer: why they choose to refuse. J Gastroenterology and Hepatology 19 (Supp) A196.

Cole SR, Young GP, Roosa N, Mehaffey S, Smith A, Esterman A, Severino J, Turnbull D. 2004. Behavioural differences between participants and non-participants in colorectal cancer screening. J Gastroenterology and Hepatology 19 (Supp) A198.

Worthley DL, Cole SR, Mehaffey S, Smith A, Turnbull D, Young GP. 2004. The participants’ perception of faecal occult blood test screening for colorectal cancer: a questionnaire based study. J Gastroenterology and Hepatology 19 (Supp) A219.

Cole SR, Turnbull D, Smith A, Mehaffey S, Severino J, Young GP. 2004. Psychosocial and demographic differences between participants and non-participants in bowel cancer screening. International Journal of Behavioral Medicine. 11 (Supp) 302.

Cole SR, Cadd B, Smith A, Morcom J, Young GP. 2004. Colorectal cancer screening behaviour is influenced by screening test technology. International Journal of Behavioral Medicine. 11 (Supp) 69.

Young GP, Cole S, Roosa N, Mehaffey S, Smith A, Esterman A, Severino J, Turnbull D. 2004. Behavioural differences between participants and non-participants in colorectal cancer (CRC) Screening. Gastroenterology 126 supplement

Bampton P, Sandford J, Cole SR, Smith A, Morcom J, Cadd B, Young GP. 2004. Interval fecal occult blood testing in a colonoscopy-based colorectal cancer surveillance program detects additional pathology. Gastroenterology, 126 supplement

Smith A, Young GP, Cole SR, Morcom J, Chandler H, LaPointe L. 2004. A quantifiable faecal immunochemical test (FIT) for haemoglobin facilitates balancing sensitivity with specificity when screening for colorectal cancer. Gastroenterology, 126 supplement

Smith A,Cadd B,Morcom J, Byrne D, Guy J, Cole SR,Young GP. 2003. Relationship between Ongoing Participation in Colorectal Cancer Screening and Method of Invitation. Gastroenterology, 124 Supplement.

LaPointe L, Young GP, Roy M, Chandler H. 2003.Selecting for diagnostic colonoscopy by quantifiable fecal immunochemical tests. Gastroenterology 2003. Suppl. to 124(4).

Cole SR, Smith A, Bampton P, Sandford J, Morcom J, Young GP. 2003. Screening for Colorectal Cancer: Direct Comparison of a Brush-Sampling Fecal Immunochemical Test for Hemoglobin with Hemoccult. Gastroenterology, 124 Supplement.

Ramnath GJ,Olesnicki A, Cole SR, Esterman A, Bampton P, Young GP. 2003. Yield Of Significant Neoplasia In Three Clinically Indicated Settings For Colonoscopy. Gastroenterology 124 Supplement.

Smith A,Cole SR, Morcom J, Sandford J, Bampton P, Young GP. 2003. Colorectal cancer screening: direct comparison of a brush-sampling faecal immunochemical test for haemoglobin with a guaiac FOBT. J Gastroenterology and Hepatology 18 (Supp) B24.

Bampton PA, Sandford JJ, Cadd B, Cole SR, Young GP. 2002. Interval annual faecal occult blood testing detects further lesions in a colonoscopy-based screening surveillance program. Gastroenterology. 122 Supplement:A589.

Young G, Cole SR, Cadd B, Morcom J. 2002. Population participation in screening improves markedly using an immunochemical fecal occult blood test with simplified fecal sampling. Gastroenterology 122 Supplement:A484.

Cole S, Roosa N, Young G, Turnbull D. 2002. Attitudes and barriers to colorectal cancer screening. Gastroenterology 122 Supplement:A487.

Ramnath GJ, Bampton PA, Sandford JJ, Cole S, Young GP. 2002. Screening colonoscopy vs. faecal occult blood testing: what is the yield? Journal of Gastroenterology & Hepatology. 17 Supplement:A101.

Cole SR, Sandford JJ, Cadd B, Young GP, Bampton PA. 2002. Yield of a colonoscopic based surveillance program is enhanced by interval faecal occult blood testing. Journal of Gastroenterology & Hepatology. 17 Supplement:A96.

Cole SR, Roosa N, Mehaffey S, Young GP, Turnbull D. 2002. Attitudes towards colorectal cancer screening. Journal of Gastroenterology & Hepatology. 17 Supplement:A119.

Young GP, Cole SR, Cadd B, Morcom J. 2002. Participation in colon cancer screening improves using a faecal occult blood test with improved technology. Journal of Gastroenterology & Hepatology. 17 Supplement:A120.

Cole SR, Smith A, Cadd B, Morcom J, Byrne D, Guy J, Young GP. 2002. Screening for colorectal cancer: population participation and yield over time. Journal of Gastroenterology & Hepatology. 17 Supplement:A122.

Young GP, St John DJB, Cole SR, Sinatra M, Bielecki B, Bennett J, Warren S, Pizzey C. 2002. Sensitivity and specificity for adenomas and cancers of a new quantifiable occult blood test (InSure_®). Journal of Gastroenterology & Hepatology. 17 Supplement:A122.

Cole SR, Sandford JJ, Cadd BA, Bennett J, Young GP, Bampton PA. 2001. Interval fecal occult blood testing in a colonoscopy based screening program. Gastroenterology 120 Supplement A603.

Young GP, St John DJB, Sinatra M, Cole SR, Bielecki B, Bennett J, Warren S. 2001 Evaluation of a quantifiable immunochemical fecal occult test with simplified fecal sampling. Gastroenterology 120 Supplement A599.

Cole SR, Cadd B, Sandford J, Young GP, Bampton P. 2001. Interval faecal occult blood testing in a colonoscopy based screening program. Journal of Gastroenterology & Hepatology. 16 Supplement:A17.

Cole S, Byrne D, Guy J, Morcom JM, Young G. 2000. Primary care physician involvement improves participation in colorectal cancer screening. Gastroenterology 118 Supplement:A270.

Cole, S R, Morcom J, Byrne D, Guy J, Young GP. 2000. General practitioner endorsement improves participation in colorectal cancer screening. Journal of Gastroenterology & Hepatology. 15 Supplement:J42.

Young GP, St John DJB, Sinatra MA, Bielecki B, Cole SR, Bennett J, Pizzey C, Warren S. 2000. Evaluation of a new immunochemical faecal occult blood test with simplified faecal sampling. Journal of Gastroenterology & Hepatology. 15 Supplement:J33.

Sinatra MA, Bielecki B, Young GP, St. John DJB, LaPointe L, Chandler L. 2000..Faecal haemoglobin measurement in colorectal neoplasia. J. Gastro Hepatology. 15 Suppl. J37.

Cole SR, Young GP. 1999. Dietary restriction impairs compliance with FOB screening for colorectal cancer. Gastroenterology 116 Supplement:A391

Cole, S R. Young, G P. The effect of diet restriction on compliance with screening for faecal occult blood. Journal of Gastroenterology & Hepatology. 13 Supplement:A198, November 1998.